Rhythm Pharmaceuticals, Inc. Common Stock
$98.85
$2.08 (+2.15%)
$97.21Day Range$100.85
Key Statistics
Market Cap
$6.66B
Shares Outstanding
68.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 5, 2017
Round Lot
100
Locale
US
Trading Data
Day Open
$97.69
Day High
$100.85
Day Low
$97.21
Volume
533.0K
VWAP
$99.51
Prev Close
$96.77
Transactions
--
Acc. Volume
--
About Rhythm Pharmaceuticals, Inc. Common Stock
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
PHARMACEUTICAL PREPARATIONSSIC 2834414 employees222 BERKELEY STREET, BOSTON, MA, 02116857-264-4280IPO Oct 5, 2017US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001649904
- Composite FIGI
- BBG007DLZ601
- Share Class FIGI
- BBG007DLZ629
- Ticker Root
- RYTM
- SIC Code
- 2834
About Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) Stock
Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) closed the 2026-09-16 session at $98.85, up 2.15% versus the previous close (+2.08). The stock opened at $97.69 and traded between $97.21 and $100.85 during that session. Session trading volume was 533K shares. The volume-weighted average price (VWAP) is $99.51.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Rhythm Pharmaceuticals, Inc. Common Stock has a market capitalization of $6.66 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. RYTM is listed on the XNAS exchange. The company employs approximately 414 people. Rhythm Pharmaceuticals, Inc. Common Stock is headquartered in BOSTON, MA. The recorded listing date is 2017-10-05.
On this page you can find market RYTM stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.